CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink

Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has ...
Frontiers

Transforming long-term post-acute care for the aging population through home infusion therapy in China: assurance for quality and safety of care delivery (Part 2)

China's healthcare system may benefit from the integration of home infusion therapy (HIT) combined with home health services (HHS) to address the urgent need for a sustainable long-term, post-acute ...
Frontiers

Transforming long-term post-acute care for the aging population through home infusion therapy in China: an assessment of need and demand (Part 1)

China’s healthcare system is confronting a rising burden of antimicrobial resistance, chronic complex diseases, and an aging population requiring long-term, post-acute care. As a value-based care ...
dvm360

Saving a life with therapeutic plasma exchange

A therapeutic plasma exchange (TPE) recently saved the life of a puppy that overdosed on a non-steroidal anti-inflammatory ...

CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference

CorMedix (NASDAQ:CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company’s focus ...
pharmaphorum

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings. The new ...
Medscape

Head and Neck Cancer

Dr Maurie Markman examines new data on GLP-1 agonists and cancer risk, which shows promising reductions in several cancers but concerning kidney signals.